Deep vein thrombosis detection by 99mTc-plasmin test and phlebography

Deep vein thrombosis (DVT) remains a critical clinical concern due to its potential to cause severe complications like pulmonary embolism. Traditional diagnostic methods, such as phlebography, are invasive and time-consuming. Prior research has shown that alternative imaging techniques may offer faster screening options. However, a gap remains in identifying non-invasive methods with high diagnostic accuracy. This uncertainty motivated the exploration of nuclear imaging tools like 99mTc-labeled plasmin. No prior work had resolved the balance between sensitivity and specificity in such a test. The need for rapid, reliable screening in high-risk populations is clear. Establishing a simpler diagnostic approach could improve patient outcomes. This study aimed to address those unmet clinical needs.

The study aimed to assess the diagnostic accuracy of a 99mTc-plasmin test for detecting DVT in patients with suspected deep vein thrombosis. The specific problem addressed was the need for a non-invasive, rapid screening method that could reduce reliance on conventional phlebography. The motivation stemmed from the limitations of existing diagnostic tools, including their invasiveness and time requirements. The goal was to determine whether the plasmin test could serve as a reliable initial screening tool. The researchers sought to compare its performance against phlebography in terms of sensitivity and specificity. They also aimed to evaluate its practicality for use in high-risk patient groups. The study focused on calf, popliteal, and femoral vein thrombosis detection. The findings could inform clinical protocols for DVT screening.

The study evaluated the 99mTc-plasmin test in 63 patients suspected of having DVT. Each patient underwent both the plasmin test and conventional phlebography as a reference standard. The test involved labeling plasmin with 99mTc and administering it to detect thrombus formation. Diagnostic sensitivity and specificity were calculated by comparing test results with phlebography findings. The predictive values for positive and negative test outcomes were also determined. The study focused on three anatomical regions: calf, popliteal, and femoral veins. Data were analyzed to assess regional variations in test performance. The aim was to determine whether the test could reliably identify DVT in high-risk patients.

The 99mTc-plasmin test demonstrated a sensitivity of 0.97 and a specificity of 0.55 when compared to phlebography. The positive predictive value was 0.79, and the negative predictive value was 0.92. Sensitivity was highest in the calf and popliteal regions but lower in the femoral veins. Specificity was higher for femoral vein thrombosis compared to other regions. These findings suggest the test is effective for initial screening but requires confirmation with phlebography. The test's high negative predictive value supports its use in ruling out DVT. The results indicate that the plasmin test is suitable for high-risk patients. However, positive results must be verified through conventional imaging.

The 99mTc-plasmin test is suitable for DVT screening in high-risk patient groups. The authors propose that it is a simple and rapid diagnostic tool for initial assessment. The test's high sensitivity supports its use in identifying potential DVT cases. However, the moderate specificity suggests the need for confirmation with phlebography. The findings indicate that the test is most effective for calf and popliteal vein thrombosis detection. The authors suggest that it may not be as reliable for femoral vein thrombosis. The test's rapid nature makes it practical for clinical use. The authors emphasize that positive results should be verified through conventional methods.